Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain ...Middle East

GUANGZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4. FZ002-037 is a highly selective oral...

Hence then, the article about fermion and simcere enter into an exclusive license and collaboration agreement for china s first sstr4 agonist targeting pain was published today ( Saturday 18/01/2025 - 07:50 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain )

Also on site :

• The Iconic San Francisco Hotel Where Tony Bennett First Left His Heart Turns 119 Today
• Payment Networks Ready Infrastructure for Agentic Commerce at Scale .. PYMNTS.com
• ‘I can’t feel my leg’: Israeli gunfire disables teenagers in West Bank